Sources: Alphabet's Verily is looking for partners to co-develop shoes with embedded sensors to track the wearer's movement, weight, and detect falls
Christina Farr / CNBC :
Context & Ripple Effects
The shoe report slots into a two-year build-out of Verily's commercial ambitions. After Temasek's minority-stake investment in 2017, the division moved toward taking on patient risk through joint contract bids with insurers, then signed clinical-trials partnerships with Novartis, Sanofi, Otsuka, and Pfizer months after this story.
What makes the footwear push notable is the population it implies: movement, weight, and fall tracking point at elderly and at-risk patients — the same cohorts insurers would underwrite — sensed passively through something people already wear rather than a device they must adopt.
First-order effects
- Co-development partners — footwear brands or device manufacturers — would get Alphabet's sensor stack inside their product line, while Verily gains a distribution channel it does not have to build alone.
- Insurers already in talks with Verily on risk-bearing contracts gain a candidate data source for exactly the outcomes (falls, mobility decline) that drive costs in covered populations.
Second-order effects
- Alphabet's later offer to buy Fitbit shows the same hardware appetite playing out through M&A as well as partnerships — wearable makers face a buyer that can fund both routes.
- If shoe-based sensing reaches payers before rivals, competing wearable vendors must decide whether to license into Verily's pipeline or counter with their own elder-care form factors.
Third-order effects
- The pattern across these moves — sensors, insurer risk contracts, pharma trials, and the $700M raise earmarked for expanding commercial businesses — points toward Verily consolidating into a vertically integrated health-data platform inside Alphabet, with the attendant scrutiny over who controls longitudinal patient data.
The trend: Alphabet is assembling Verily into a full-stack health company where its own sensors feed services sold to insurers and pharma, with each partnership adding another layer of the stack.